




Weekly Investment Focus

26 September 2022

"THE TREND IS YOUR FRIEND"

- Over the last nine months, equity markets have fallen by -21%.
- Despite this, 20% of listed companies managed to generate positive performance
- ♦ Stocks with strong fundamentals will increase their lead ...
- ... at least until the Fed "pivots" by stopping its hiking process

CHART OF THE WEEK: "The bear market does not shake all companies"



STOCK MARKET ANALYSIS


This week, let's turn the tables. Rather than forecasting the economic cycle and its impact on the equity market or digging into the accounting details of companies to identify the most successful ones, let's look at the best performing stocks year to date. First, while the global equity market was down -21% (MSCI All Countries World Index), the energy sector had a double-digit positive return of +17%. Following the post-Covid reopening of economies and Russia's invasion of Ukraine, oil and gas prices have soared, boosting the profits of companies in the sector. All other segments are in negative territory (see Fig. 2),



starting with communication services, technology, and consumer discretionary. They are the most cyclical and therefore suffer more in times of recession. In contrast, utilities, healthcare, and consumer staples have shown resilience. These sectors were more resilient to the bear market.

Fig. 2 - Stock market performance 2022, by sector

Fig. 3 - Distribution of stock market performance



Breaking down the 1,100 largest US and European companies (S&P 500 and Stoxx 600) in a more granular way, 20% of the companies have managed to deliver positive returns over the last nine months (see Fig. 3). Once again, of the 35 companies active in the energy sector, 30 have a positive performance and more than half are between +30% and +60%. The top performer was <u>Occidental Petroleum</u>, with an appreciation of +122%. As long as the geopolitical situation in Europe remains conflictual, the energy sector will benefit.

Fig. 4 - Scoring of US and European companies by different criteria

Rank	Name	Performance 2022 YtD	12-month Sales Growth	Debt / Ebitda Ratio	Price / Earnings Ratio	Scoring	Sector	Country	Ticker
1	MERCK & CO. INC.	12%	36%	1.4 x	12.8 x	60	Pharmaceuticals	United States	MRK UN
2	NOVO NORDISK A/S-B	0%	21%	0.4 x	26.8 x	55	Pharmaceuticals	Denmark	NOVOB DC
3	VERTEX PHARMACEUTICALS INC	31%	25%	0.2 x	19.6 x	54	Biotechnology	United States	VRTX UW
4	REGENERON PHARMACEUTICALS	12%	15%	0.4 x	17.3 x	52	Biotechnology	United States	REGN UW
5	GLENCORE PLC	37%	48%	1.1 x	5.0 x	51	Metals & Mining	Switzerland	GLEN LN
6	ASTRAZENECA PLC	16%	49%	4.2 x	17.2 x	51	Pharmaceuticals	Britain	AZN LN
7	ABBVIE INC	5%	7%	2.8 x	10.7 x	49	Biotechnology	United States	ABBV UN
8	DEUTSCHE TELEKOM AG-REG	15%	5%	3.7 x	12.2 x	48	Telecommunication	Germany	DTE GY
9	BAYER AG-REG	11%	16%	3.8 x	6.8 x	48	Pharmaceuticals	Germany	BAYN GY
10	AMGEN INC	1%	4%	2.9 x	12.7 x	47	Biotechnology	United States	AMGN UW
11	BRISTOL-MYERS SQUIBB CO	12%	6%	2.3 x	8.6 x	47	Pharmaceuticals	United States	BMY UN
12	PHILIP MORRIS INTERNATIONAL	1%	6%	2.0 x	17.0 x	47	Tobacco	United States	PM ONE
13	COCA-COLA CO/THE	1%	13%	3.6 x	23.9 x	46	Beverages	United States	KO ONE
14	HSBC HOLDINGS PLC	19%	0%	n.a.	7.3 x	45	Banks	Britain	HSBA LN
15	ZURICH INSURANCE GROUP AG	6%	-32%	n.a.	13.0 x	45	Insurance	Switzerland	ZURN SE
16	ELI LILLY & CO	9%	9%	1.9 x	36.9 x	45	Pharmaceuticals	United States	LLY UN
17	ELEVANCE HEALTH INC	3%	15%	2.4 x	15.6 x	43	Health Care Providers	United States	ELV UN
18	BRITISH AMERICAN TOBACCO PLC	27%	3%	4.4 x	15.0 x	42	Tobacco	Britain	BATS LN
19	METLIFE INC	5%	-2%	n.a.	8.8 x	41	Insurance	United States	PUT A
20	DEERE & CO	4%	14%	4.8 x	13.2 x	41	Machinery	United States	FROM ONE



Let's move on from the energy companies and focus on the other 188 companies, both US and European, that have been in positive territory so far this year. They were scanned and ranked to give them good or bad scores on 16 criteria: sales and earnings growth, debt ratios, valuation ratios, momentum indicators, etc. In the end, we kept only the large caps in this scoring, as they are often the outperformers in times of market turmoil (see Fig. 4).

Fig. 5 & 6 - US & European healthcare companies



Of the 20 companies that came out on top of this screening and whose joint performance was remarkable in 2022 (see Chart of the Week), a very large majority are listed in the United States. The strength of the dollar did not penalise them. At the other end of the spectrum, we note the low representation of eurodenominated securities and the absence of French securities. Also relevant, more than half of the Top 20 are healthcare companies, six "pharmas" and four "biotechs": Merck, Novo Nordisk, Astrazeneca, Bayer, Bristol-Myers, Eli Lilly (see Figs. 5 & 6) and Vertex, Regeneron, Abbvie, Amgen (see Fig. 7).

Fig. 7 - Biotechnology companies

Fig. 8 - Consumer staples companies 150 150 150 150 Regeneron Pharmaceuticals Inc Coca-Cola Co/The Vertex Pharmaceuticals Inc Philip Morris International Inc 140 140 140 AbbVie Inc British American Tobacco PLC Amgen Ind 130 130 130 130 120 120 120 120 110 110 110 110 100 100 100 100 90 90 90 90 80 80 Mav.2022 Mav.2022 Jul.2022 Sep.2022 Nov.2022



They are accompanied by three consumer staples companies: <u>Coca Cola</u>, <u>Philip Morris</u> and <u>British American Tobacco</u> (see Fig. 8). It is a long way from concluding that consumers are switching from food and heating to smoking and drinking sodas.

Fig. 9 - Financial companies

Fig. 10 - Other sectors companies



Three financials also belong to this ranking: <u>HSBC</u>, <u>Zurich Insurance</u> and <u>Metlife</u> (see Fig. 9). **The last four companies featured do not belong to the sectors previously mentioned: the miner <u>Glencore</u>, the operator <u>Deutsche Telekom</u>, the healthcare service provider <u>Elevance</u>, and the agricultural equipment manufacturer <u>Deere</u> (see Fig. 10). Finally, utilities are conspicuous by their absence, even though this defensive sector as a whole has delivered a decent relative performance. Utilities seem doomed to gloom.**

Conclusion:

Around 20% of listed companies have performed positively since the beginning of the year. As usual, stock-picking is a winning game. Companies with solid fundamentals should be able to extend their lead over the next few months: sales growth, market share gains, low debt levels to be less affected by rising interest rates, undervaluation, etc.

For how long? Probably until the US Federal Reserve "pivots" by halting or even reducing its key rate hikes. If this game changer occurs quickly enough for economic activity to recover, it could end the bear market and prompt a sector rotation. The sooner the better, but until then, investors will stick to the popular idiom: the trend is your friend.



RETURN ON FINANCIAL ASSETS

Markets Performances (local currencies)	Last Momentum Price Indicator (RS		1-Week (%)	1-Month (%)	2022 Year-to-Date (%)	2021 (%)	2020 (%)
Equities							
World (MSCI)	567.9	25.33	-5.0%	-10.3%	-23.4%	19.0%	16.9%
JSA (S&P 500)	3 693	28.90	-4.6%	-10.4%	-21.6%	28.7%	18.4%
JSA (Dow Jones)	29 590	27.39	-4.0%	-9.9%	-17.3%	20.9%	9.7%
JSA (Nasdaq)	10 868	29.90	-5.1%	-12.2%	-30.1%	22.2%	45.0%
uro Area (DJ EuroStoxx)	368.2	29.83	-4.6%	-8.5%	-20.8%	23.5%	0.8%
					-2.1%		-11.4%
JK (FTSE 100)	7 019	32.35	-3.0%	-6.2%		18.4%	
witzerland (SMI)	10 138	22.58	-4.3%	-7.2%	-19.0%	23.7%	4.3%
apan (Nikkei)	26 432	38.77	-2.6%	-5.6%	-4.6%	6.7%	18.3%
merging (MSCI)	906	24.22	-4.0%	-8.2%	-24.5%	-2.3%	18.8%
rasil (IBOVESPA)	111 716	52.85	2.2%	-1.0%	6.6%	-11.9%	2.9%
tussia (MOEX)	2 090	31.85	-14.2%	-7.5%	-43.4%	21.9%	14.8%
ndia (SENSEX)	57 164	42.43	-1.3%	-1.6%	0.8%	23.2%	17.2%
hina (CSI)	3 854	26.46	-1.9%	-7.2%	-20.4%	-3.5%	29.9%
communication Serv. (MSCI Work	71.05	22.90	-5.1%	-11.7%	-35.0%	10.9%	24.2%
•							
onsumer Discret. (MSCI World)	287.1	28.90	-6.7%	-10.4%	-29.4%	9.2%	37.0%
onsumer Staples (MSCI World)	247.1	24.65	-2.9%	-8.2%	-13.7%	11.7%	8.8%
nergy (MSCI World)	204.2	29.64	-8.2%	-12.7%	12.6%	37.5%	-27.7%
inancials (MSCI World)	119.8	29.24	-5.3%	-7.4%	-18.3%	25.1%	-3.1%
ealth Care (MSCI World)	304.8	28.44	-4.2%	-6.7%	-16.3%	18.0%	15.4%
earth care (MSCI World)					-24.2%		11.8%
•	247.8	24.64	-4.9%	-11.6%		16.6%	
rfo. Tech. (MSCI World)	387.0	27.26	-4.0%	-13.3%	-32.1%	27.6%	46.2%
laterials (MSCI World)	269.8	27.78	-5.3%	-11.3%	-23.4%	15.4%	21.6%
eal Estate (MSCI World)	171.0	21.72	-6.3%	-10.9%	-25.4%	23.6%	-5.7%
tilities (MSCI World)	149.2	28.88	-3.9%	-7.0%	-5.9%	11.1%	4.8%
onds (FTSE)	2	20.55	4 40	4 ***	45.00		2 22/
ISA (7-10 Yr)	3.77%	28.04	-1.4%	-4.1%	-13.9%	-2.4%	9.3%
uro Area (7-10 Yr)	2.79%	24.88	-2.1%	-5.3%	-16.9%	-2.9%	4.5%
iermany (7-10 Yr)	2.11%	25.82	-1.6%	-4.7%	-14.6%	-2.7%	3.0%
JK (7-10 Yr)	3.83%	13.11	-5.2%	-9.5%	-19.0%	-4.9%	5.4%
witzerland (7-10 Yr)	1.41%	22.11	-1.8%	-4.2%	-12.3%	-2.3%	0.4%
apan (5-10 Yr)	0.25%	43.97	0.1%	-0.4%	-1.2%	0.0%	-0.1%
* *							
merging (5-10 Yr)	8.29%	26.99	-2.1%	-5.0%	-21.4%	-2.3%	5.2%
ISA (IG Corp.)	5.43%	26.80	-1.5%	-4.6%	-17.2%	-1.0%	9.9%
uro Area (IG Corp.)	4.04%	22.65	-1.5%	-3.6%	-13.8%	-1.0%	2.8%
		21.29	-1.3%	-3.4%	-17.7%	-3.0%	8.1%
merging (IG Corp.)	8.24%	21.29	-1.5%	-5.4%	-1/.//p	-3.0%	8.1%
JSA (HY Corp.)	9.25%	26.26	-1.9%	-4.2%	-13.6%	5.3%	7.1%
uro Area (HY Corp.)	8.03%	26.92	-1.4%	-3.1%	-13.0%	3.4%	2.3%
merging (HY Corp.)	11.82%	30.60	-2.0%	-4.0%	-18.2%	-3.2%	4.3%
ineignig (HT Corp.)	11.02/0	30.00	-2.0/8	-4.0/8	-10.2/0	-3.2/0	4.3/6
World (Convertibles)	347.9	25.97	-4.0%	-5.9%	-20.6%	2.4%	38.8%
JSA (Convertibles)	469.0	28.05	-4.2%	-6.0%	-20.9%	3.1%	54.5%
uro Area (Convertibles)	3 396	18.42	-2.6%	-6.1%	-17.3%	-0.3%	6.1%
					-9.1%		
witzerland (Convertibles)	169.0	18.71	-0.7%	-2.5%		-0.5%	0.5%
apan (Convertibles)	199.2	57.31	-0.1%	0.5%	-0.8%	3.3%	2.8%
edge Funds (Crédit Suisse)							
edge Funds Indus.	733	65.50	n.a.	0.5%	0.8%	8.2%	6.4%
istressed	940	57.10		1.7%	-2.8%	12.5%	3.8%
	763		n.a.				7.0%
vent Driven		54.17	n.a.		-6.0%	12.9%	
ixed Income	384	50.89	n.a.	0.0%	-2.3%	5.2%	3.6%
ilobal Macro	1469	78.93	n.a.	2.1%	21.9%	9.6%	6.5%
ong/Short	851	47.05	n.a.	-1.3%	-8.3%	8.3%	7.9%
TA's	407	51.62	n.a.	3.1%	19.2%	8.2%	1.9%
Narket Neutral	287	52.35		1.5%	-1.2%	6.2%	1.7%
Nulti-Strategy	694	59.23	n.a. n.a.	0.8%	-0.4%	7.0%	5.6%
-unit offategy		55.25		0.070			
olatility/							
/IX /STOXX	29.92 30.00	65.71 63.74	13.8% 13.5%	24.1% 11.4%	73.8% 55.7%	-24.3% -17.6%	65.1% 67.5%
310/00	30.00	03.74	13.370	11.470	33.770	17.070	07.570
ommodities					_		
ommodities (CRB)	560.3	n.a.	-1.5%	-5.2%	-3.1%	30.3%	10.5%
iold (Troy Ounce)	1 638	28.78	-2.3%	-5.8%	-10.5%	-3.6%	25.1%
Oil (WTI, Barrel)	79.24	33.14	-7.6%	-16.1%	2.9%	58.7%	-20.5%
il (Brent, Barrel)	83.87	32.81	-6.5%	-14.1%	10.6%	51.4%	-23.0%
in (Dient, Dallel)	03.0/	32.01	-0.3/0	-14.1/0	10.0/0	31.470	-23.070
urrencies (vs USD)							
ISD (Dollar Index)	113.69	79.30	3.6%	4.5%	18.8%	6.4%	-6.7%
UR	0.9648	26.93	-3.8%	-3.2%	-15.1%	-7.5%	9.7%
РУ			-0.5%	-4.4%	-20.0%		5.1%
	143.92	37.49					
BP	1.0611	14.11	-7.2%	-9.6%	-21.6%	-1.0%	3.1%
UD	0.6495	28.49	-3.4%	-5.8%	-10.6%	-5.6%	9.6%
AD	1.3629	21.86	-2.8%	-4.4%	-7.3%	0.7%	2.1%
HF	0.9863	33.65	-2.2%	-2.1%	-7.4%	-3.0%	9.4%
NY	7.1636	14.81	-2.2%	-4.1%	-11.3%	2.7%	6.7%
IXN	20.302	41.47	-1.9%	-1.3%	1.1%	-3.0%	-5.0%
A A A Town Construction A.	1 597.8	19.01	-1.1%	-2.9%	-7.9%	0.9%	3.3%
M (Emerging Index)							



DISCLAIMER

This document is issued by Atlantic Financial Group (hereinafter "Atlantic"). It is not intended for distribution, publication, or use in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it aimed at any person or entity to whom it would be unlawful to address such a document.

This document is provided for information purposes only. It does not constitute an offer or a recommendation to subscribe to, purchase, sell or hold any security or financial instrument. It contains the opinions of Atlantic, as at the date of issue. These opinions and the information herein contained do not take into account an individual's specific circumstances, objectives, or needs. No representation is made that any investment or strategy is suitable or appropriate to individual circumstances or that any investment or strategy constitutes a personal recommendation to any investor. Each investor must make his/her own independent decisions regarding any securities or financial instruments mentioned herein. Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Atlantic does not provide tax advice. Therefore, you must verify the above and all other information provided in the document or otherwise review it with your external tax advisors.

Investment are subject to a variety of risks. Before entering into any transaction, an investor should consult his/her investment advisor and, where necessary, obtain independent professional advice in respect of risks, as well as any legal, regulatory, credit, tax, and accounting consequences. The information and analysis contained herein are based on sources considered to be reliable. However, Atlantic does not guarantee the timeliness, accuracy, or completeness of the information contained in this document, nor does it accept any liability for any loss or damage resulting from its use. All information and opinions as well as the prices, market valuations and calculations indicated herein may change without notice. Past performance is no guarantee of current or future returns, and the investor may receive back less than he invested. The investments mentioned in this document may carry risks that are difficult to quantify and integrate into an investment assessment. In general, products such as equities, bonds, securities lending, forex, or money market instruments bear risks, which are higher in the case of derivative, structured, and private equity products; these are aimed solely at investors who are able to understand their nature and characteristics and to and bear their associated risks. On request, Atlantic will be pleased to provide investors with more detailed information concerning risks associated with given instruments.

The value of any investment in a currency other than the base currency of a portfolio is subject to the foreign exchange rates. These rates may fluctuate and adversely affect the value of the investment when it is realized and converted back into the investor's base currency. The liquidity of an investment is subject to supply and demand. Some products may not have a well-established secondary market or in extreme market conditions may be difficult to value, resulting in price volatility and making it difficult to obtain a price to dispose of the asset. If opinions from financial analysts are contained herein, such analysts attest that all of the opinions expressed accurately reflect their personal views about any given instruments. In order to ensure their independence, financial analysts are expressly prohibited from owning any securities that belong to the research universe they cover. Atlantic may hold positions in securities as referred to in this document for and on behalf of its clients and/or such securities may be included in the portfolios of investment funds as managed by Atlantic.